Newsfeeds Archive - Spark Newswire

2 minute read

Dr. Reddy’s Laboratories Ltd. And Bayer Entered Into A Partnership To Market And Distribute A Second Brand Of Vericiguat In India. Under The Terms Of This Agreement, Bayer Has Granted Non-Exclusive Rights To Dr. Reddy’s Under The Brand Name Gantra

April 5, 9:46 AM

- SEC Filing Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, hereafter referred to as "Dr. Reddy's")) and Bayer announced that both companies have entered into a partnership to

RDY

1 minute read

Earnings

Dr Reddy’s Laboratories: Q3 Earnings Insights

By Benzinga Insights

January 30, 6:50 AM

Dr Reddy’s Laboratories (NYSE:RDY) reported its Q3 earnings results on Tuesday, January 30, 2024 at 01:30 PM. Here’s…

RDY

1 minute read

Reported Earlier, ‘India’s Dr. Reddy’s Shares Fall On Observations From U.S. Drug Regulator’ – Reuters News

By Benzinga Newsdesk

December 11, 2:41 PM

https://www.reuters.com/business/healthcare-pharmaceuticals/indias-dr-reddys-shares-fall-observations-us-regulator-2023-12-11/ Shares of Indian drugmaker Dr. Reddy's Laboratories (REDY.NS) were down 5.8% on Monday

RDY

2 minute read

Top 5 Health Care Stocks That May Fall Off A Cliff

By Lisa Levin

August 23, 7:58 AM

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

CAPR

2 minute read

Why Are Journey Medical Shares Trading Lower Today?

By Vandana Singh

July 11, 12:53 PM

Journey Medical Corporation (NASDAQ: DERM) shares are trading lower after the company announced topline results from the two Phase 3 trials, evaluating Minocycline Hydrochloride Modified Release Capsules (DFD-29) for adult patients with moderate-to-severe

DERM

1 minute read

Why Are Journey Medical Shares Trading Higher Today

By Vandana Singh

June 13, 10:11 AM

Journey Medical Corporation (NASDAQ: DERM) announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the

DERM

1 minute read

Why Aditxt Shares Are Surging Today

By Nabaparna Bhattacharya

April 20, 2:20 PM

Aditxt, Inc. (NASDAQ: ADTX) stock is surging Thursday as it expands its portfolio to include innovative therapies for infectious diseases.

ADTX

2 minute read

Aditxt Signs Asset Purchase Agreement To Acquire 50% Ownership Of Global Response Aid With Rights To Manufacture And Market Broad-Spectrum Antiviral Drug Avigan; The Consideration For The Transaction Is $24.5M

By Happy Mohamed

April 20, 8:17 AM

This agreement is a significant step for Aditxt as it expands its portfolio to include innovative therapies for infectious diseases; Aditxt will partner with global logistics leader Agility to address a growing global

ADTX

1 minute read

Dr. Reddy’s Seeks Gaining Foothold In Women’s Health Via Mayne Pharma’s U.S. Generic Prescription Deal

By Vandana Singh

February 27, 2:04 PM

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) has agreed to acquire the U.S. generic prescription product portfolio of Australia-based Mayne Pharma Group Limited (OTC:MAYND) (OTC:MAYNF)…

MAYND

1 minute read

M&A
News

Dr. Reddy’s Laboratories Announced Late Sunday Agreement To Acquire Mayne Pharma’s U.S. Generic Prescription Product Portfolio

By Charles Gross

February 27, 6:27 AM

Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd. (NYSE: RDY) announced that it has entered into a definitive agreement to acquire the U.S. generic prescription product portfolio of Salisbury, Australia, based Mayne Pharma Group Limited (ASX: MYX).

RDY